Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis

Trial Profile

Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2017

At a glance

  • Drugs CTV 05 (Primary) ; Metronidazole
  • Indications Bacterial vaginosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Jun 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Sep 2017.
    • 11 May 2016 Company expects completion of this trial in early 2018, according to an Osel Inc. media release.
    • 11 May 2016 Status changed from not yet recruiting to recruiting, according to an Osel Inc. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top